{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T06:11:03Z","timestamp":1763705463383},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2018,6,28]],"date-time":"2018-06-28T00:00:00Z","timestamp":1530144000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Z Rheumatol"],"published-print":{"date-parts":[[2018,9]]},"DOI":"10.1007\/s00393-018-0496-4","type":"journal-article","created":{"date-parts":[[2018,6,28]],"date-time":"2018-06-28T07:29:56Z","timestamp":1530170996000},"page":"593-608","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Lupusnephritis"],"prefix":"10.1007","volume":"77","author":[{"given":"S.","family":"Melderis","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Wiech","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Iking-Konert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"O. M.","family":"Steinmetz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,6,28]]},"reference":[{"issue":"2","key":"496_CR1","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1093\/rheumatology\/kev311","volume":"55","author":"JG Hanly","year":"2016","unstructured":"Hanly JG et\u00a0al (2016) The frequency and outcome of lupus nephritis: results from an international inception cohort study. Rheumatology (Oxford) 55(2):252\u2013262","journal-title":"Rheumatology (Oxford)"},{"issue":"3","key":"496_CR2","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1016\/j.kint.2016.05.017","volume":"90","author":"HJ Anders","year":"2016","unstructured":"Anders HJ, Rovin B (2016) A pathophysiology-based approach to the diagnosis and treatment of lupus nephritis. Kidney Int 90(3):493\u2013501","journal-title":"Kidney Int"},{"issue":"2","key":"496_CR3","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1159\/000438844","volume":"1","author":"V Tesar","year":"2015","unstructured":"Tesar V, Hruskova Lupus Nephritis Z (2015) A different disease in European patients? Kidney Dis (basel) 1(2):110\u2013118","journal-title":"Kidney Dis (basel)"},{"issue":"5","key":"496_CR4","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1136\/ard.62.5.435","volume":"62","author":"C Fiehn","year":"2003","unstructured":"Fiehn C et\u00a0al (2003) Improved clinical outcome of lupus nephritis during the past decade: importance of early diagnosis and treatment. Ann Rheum Dis 62(5):435\u2013439","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"496_CR5","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1093\/ckj\/sfv072","volume":"8","author":"HJ Anders","year":"2015","unstructured":"Anders HJ, Weidenbusch M, Rovin B (2015) Unmet medical needs in lupus nephritis: solutions through evidence-based, personalized medicine. Clin Kidney\u00a0J 8(5):492\u2013502","journal-title":"Clin Kidney J"},{"issue":"3","key":"496_CR6","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1002\/cpt.729","volume":"102","author":"AS Levey","year":"2017","unstructured":"Levey AS, Inker LA (2017) Assessment of glomerular filtration rate in health and disease: a state of the art review. Clin Pharmacol Ther 102(3):405\u2013419","journal-title":"Clin Pharmacol Ther"},{"issue":"5","key":"496_CR7","doi-asserted-by":"publisher","first-page":"825","DOI":"10.2215\/CJN.05780616","volume":"12","author":"S Almaani","year":"2017","unstructured":"Almaani S, Meara A, Rovin BH (2017) Update on lupus nephritis. Clin J Am Soc Nephrol 12(5):825\u2013835","journal-title":"Clin J Am Soc Nephrol"},{"issue":"4","key":"496_CR8","first-page":"598","volume":"35","author":"A Flechsig","year":"2017","unstructured":"Flechsig A et al (2017) What is the clinical significance of anti-Sm antibodies in systemic lupus erythematosus? A comparison with anti-dsDNA antibodies and C3. Clin Exp Rheumatol 35(4):598\u2013606","journal-title":"Clin Exp Rheumatol"},{"issue":"1","key":"496_CR9","first-page":"84","volume":"35","author":"MJ Siedner","year":"2008","unstructured":"Siedner MJ et al (2008) Diagnostic accuracy study of urine dipstick in relation to 24-hour measurement as a\u00a0screening tool for proteinuria in lupus nephritis. J\u00a0Rheumatol 35(1):84\u201390","journal-title":"J Rheumatol"},{"issue":"2","key":"496_CR10","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1097\/01.ASN.0000108969.21691.5D","volume":"15","author":"JJ Weening","year":"2004","unstructured":"Weening JJ (2004) The classification of glomerulonephritis in systemic lupus erythematosus revisited. J\u00a0Am Soc Nephrol 15(2):241\u2013250","journal-title":"J Am Soc Nephrol"},{"issue":"4","key":"496_CR11","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1016\/j.kint.2017.11.023","volume":"93","author":"IM Bajema","year":"2018","unstructured":"Bajema IM et al (2018) Revision of the International Society of Nephrology\/Renal Pathology Society classification for lupus nephritis: clarification of definitions, and modified National Institutes of Health activity and chronicity indices. Kidney Int 93(4):789\u2013796. \n                    https:\/\/doi.org\/10.1016\/j.kint.2017.11.023","journal-title":"Kidney Int"},{"key":"496_CR12","doi-asserted-by":"publisher","DOI":"10.1007\/s40620-017-0463-1","author":"D Chen","year":"2017","unstructured":"Chen D, Hu W (2017) Lupus podocytopathy: a\u00a0distinct entity of lupus nephritis. J\u00a0Nephrol. \n                    https:\/\/doi.org\/10.1007\/s40620-017-0463-1","journal-title":"J Nephrol"},{"issue":"4","key":"496_CR13","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1038\/ki.2012.409","volume":"83","author":"LH Wu","year":"2013","unstructured":"Wu LH et\u00a0al (2013) Inclusion of renal vascular lesions in the 2003 ISN\/RPS system for classifying lupus nephritis improves renal outcome predictions. Kidney Int 83(4):715\u2013723","journal-title":"Kidney Int"},{"issue":"31\u201332","key":"496_CR14","first-page":"2072","volume":"100","author":"UO Wenzel","year":"2003","unstructured":"Wenzel UO et al (2003) Hemmung der Progression von chronischen Nierenerkrankungen: Therapie durch Blockierung des Renin-Angiotensin-Systems. Dtsch Arztebl Int 100(31\u201332):2072","journal-title":"Dtsch Arztebl Int"},{"issue":"6","key":"496_CR15","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1002\/art.24538","volume":"61","author":"GJ Pons-Estel","year":"2009","unstructured":"Pons-Estel GJ et al (2009) Protective effect of hydroxychloroquine on renal damage in patients with lupus nephritis: LXV, data from a\u00a0multiethnic US cohort. Arthritis Rheum 61(6):830\u2013839","journal-title":"Arthritis Rheum"},{"issue":"6","key":"496_CR16","doi-asserted-by":"publisher","first-page":"e167","DOI":"10.1016\/j.lpm.2014.03.007","volume":"43","author":"N Costedoat-Chalumeau","year":"2014","unstructured":"Costedoat-Chalumeau N et al (2014) Hydroxychloroquine: a\u00a0multifaceted treatment in lupus. Presse Med 43(6):e167\u201380","journal-title":"Presse Med."},{"key":"496_CR17","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1038\/kisup.2012.9","volume":"2","author":"DC Cattran","year":"2012","unstructured":"Cattran DC et\u00a0al (2012) Kidney disease: Improving global outcomes (KDIGO) glomerulonephritis work group. KDIGO clinical practice guideline for glomerulonephritis. Kidney Int Supplements 2:139\u2013274. \n                    https:\/\/doi.org\/10.1038\/kisup.2012.9","journal-title":"Kidney Int Supplements"},{"issue":"6","key":"496_CR18","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1093\/ndt\/gfv102","volume":"31","author":"S Wilhelmus","year":"2016","unstructured":"Wilhelmus S et\u00a0al (2016) Lupus nephritis management guidelines compared. Nephrol Dial Transplant 31(6):904\u2013913","journal-title":"Nephrol Dial Transplant"},{"issue":"11","key":"496_CR19","doi-asserted-by":"publisher","first-page":"1771","DOI":"10.1136\/annrheumdis-2012-201940","volume":"71","author":"GK Bertsias","year":"2012","unstructured":"Bertsias GK et al (2012) Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR\/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. Ann Rheum Dis 71(11):1771\u20131782","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"496_CR20","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1002\/acr.21664","volume":"64","author":"BH Hahn","year":"2012","unstructured":"Hahn BH et\u00a0al (2012) American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis. Arthritis Care Res (Hoboken) 64(6):797\u2013808","journal-title":"Arthritis Care Res. (Hoboken)"},{"issue":"6","key":"496_CR21","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1007\/s00393-013-1213-y","volume":"72","author":"M Aringer","year":"2013","unstructured":"Aringer M et\u00a0al (2013) Statement on the use of mycophenolate mofetil for systemic lupus erythematosus. Z\u00a0Rheumatol 72(6):575\u2013580","journal-title":"Z Rheumatol"},{"issue":"10","key":"496_CR22","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1056\/NEJM198603063141004","volume":"314","author":"HA Austin 3rd","year":"1986","unstructured":"Austin HA 3rd et\u00a0al (1986) Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs. N\u00a0Engl J Med 314(10):614\u2013619","journal-title":"N Engl J Med"},{"issue":"1","key":"496_CR23","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1136\/ard.2008.102533","volume":"69","author":"FA Houssiau","year":"2010","unstructured":"Houssiau FA et al (2010) The 10-year follow-up data of the Euro-Lupus Nephritis Trial comparing low-dose and high-dose intravenous cyclophosphamide. Ann Rheum Dis 69(1):61\u201364","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"496_CR24","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1681\/ASN.2008101028","volume":"20","author":"GB Appel","year":"2009","unstructured":"Appel GB et\u00a0al (2009) Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J\u00a0Am Soc Nephrol 20(5):1103\u20131112","journal-title":"J Am Soc Nephrol"},{"issue":"1","key":"496_CR25","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1038\/ki.2015.318","volume":"89","author":"M Rathi","year":"2016","unstructured":"Rathi M et al (2016) Comparison of low-dose intravenous cyclophosphamide with oral mycophenolate mofetil in the treatment of lupus nephritis. Kidney Int 89(1):235\u2013242","journal-title":"Kidney Int"},{"key":"496_CR26","unstructured":"Bundesministerium f\u00fcr Gesundheit (2017) Bekanntmachung eines Beschlusses des Gemeinsamen Bundesausschusses \u00fcber eine \u00c4nderung der Arzneimittel-Richtlinie (AM-RL): Anlage VI \u2013 Off-Label-Use Mycophenolatmofetil\/Mycophenolens\u00e4ure bei Lupusnephritis; vom: 21.09.2017."},{"issue":"8","key":"496_CR27","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.1681\/ASN.2006111300","volume":"18","author":"RJ Glassock","year":"2007","unstructured":"Glassock RJ (2007) Prophylactic anticoagulation in nephrotic syndrome: a\u00a0clinical conundrum. J\u00a0Am Soc Nephrol 18(8):2221\u20132225","journal-title":"J Am Soc Nephrol"},{"issue":"21","key":"496_CR28","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1056\/NEJMoa043731","volume":"353","author":"EM Ginzler","year":"2005","unstructured":"Ginzler EM et\u00a0al (2005) Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N\u00a0Engl J Med 353(21):2219\u20132228","journal-title":"N Engl J Med"},{"issue":"1","key":"496_CR29","doi-asserted-by":"publisher","first-page":"18","DOI":"10.7326\/M14-1030","volume":"162","author":"Z Liu","year":"2015","unstructured":"Liu Z et\u00a0al (2015) Multitarget therapy for induction treatment of lupus nephritis: a\u00a0randomized trial. Ann Intern Med 162(1):18\u201326","journal-title":"Ann Intern Med"},{"issue":"12","key":"496_CR30","doi-asserted-by":"publisher","first-page":"3671","DOI":"10.1681\/ASN.2017030263","volume":"28","author":"H Zhang","year":"2017","unstructured":"Zhang H et\u00a0al (2017) Multitarget therapy for maintenance treatment of lupus nephritis. J\u00a0Am Soc Nephrol 28(12):3671\u20133678","journal-title":"J Am Soc Nephrol"},{"issue":"4","key":"496_CR31","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1002\/art.34359","volume":"64","author":"BH Rovin","year":"2012","unstructured":"Rovin BH et\u00a0al (2012) Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the lupus nephritis assessment with rituximab study. Arthritis Rheum 64(4):1215\u20131226","journal-title":"Arthritis Rheum"},{"issue":"8","key":"496_CR32","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1111\/imj.13136","volume":"46","author":"P Kotagiri","year":"2016","unstructured":"Kotagiri P et al (2016) Single-dose rituximab in refractory lupus nephritis. Intern Med\u00a0J 46(8):899\u2013901","journal-title":"Intern Med J"},{"issue":"3","key":"496_CR33","doi-asserted-by":"publisher","first-page":"R83","DOI":"10.1186\/ar1954","volume":"8","author":"M Vigna-Perez","year":"2006","unstructured":"Vigna-Perez M et al (2006) Clinical and immunological effects of rituximab in patients with lupus nephritis refractory to conventional therapy: a\u00a0pilot study. Arthritis Res Ther 8(3):R83","journal-title":"Arthritis Res Ther"},{"issue":"9","key":"496_CR34","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.3899\/jrheum.170226","volume":"44","author":"DYH Yap","year":"2017","unstructured":"Yap DYH et\u00a0al (2017) Longterm data on disease flares in patients with proliferative lupus nephritis in recent years. J\u00a0Rheumatol 44(9):1375\u20131383","journal-title":"J Rheumatol"},{"issue":"20","key":"496_CR35","doi-asserted-by":"publisher","first-page":"1886","DOI":"10.1056\/NEJMoa1014460","volume":"365","author":"MA Dooley","year":"2011","unstructured":"Dooley MA et\u00a0al (2011) Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis. N\u00a0Engl J Med 365(20):1886\u20131895","journal-title":"N Engl J Med"},{"issue":"12","key":"496_CR36","doi-asserted-by":"publisher","first-page":"2083","DOI":"10.1136\/ard.2010.131995","volume":"69","author":"FA Houssiau","year":"2010","unstructured":"Houssiau FA et al (2010) Azathioprine versus mycophenolate mofetil for long-term immunosuppression in lupus nephritis: results from the MAINTAIN nephritis trial. Ann Rheum Dis 69(12):2083\u20132089","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"496_CR37","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1136\/annrheumdis-2016-209519","volume":"76","author":"R Vollenhoven van","year":"2017","unstructured":"van Vollenhoven R et\u00a0al (2017) A framework for remission in SLE: consensus findings from a\u00a0large international task force on definitions of remission in SLE (DORIS). Ann Rheum Dis 76(3):554\u2013561","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"496_CR38","doi-asserted-by":"publisher","first-page":"46","DOI":"10.2215\/CJN.03280807","volume":"3","author":"YE Chen","year":"2008","unstructured":"Chen YE et\u00a0al (2008) Value of a\u00a0complete or partial remission in severe lupus nephritis. Clin J Am Soc Nephrol 3(1):46\u201353","journal-title":"Clin J Am Soc Nephrol"},{"issue":"4","key":"496_CR39","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1002\/art.10142","volume":"46","author":"GG Illei","year":"2002","unstructured":"Illei GG et al (2002) Renal flares are common in patients with severe proliferative lupus nephritis treated with pulse immunosuppressive therapy: long-term followup of a\u00a0cohort of 145 patients participating in randomized controlled studies. Arthritis Rheum 46(4):995\u20131002","journal-title":"Arthritis Rheum"},{"issue":"3","key":"496_CR40","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1016\/j.rdc.2014.04.004","volume":"40","author":"BH Rovin","year":"2014","unstructured":"Rovin BH, Parikh SV, Alvarado A (2014) The kidney biopsy in lupus nephritis: is it still relevant? Rheum Dis Clin North Am 40(3):537\u2013552","journal-title":"Rheum Dis Clin North Am"},{"issue":"8","key":"496_CR41","doi-asserted-by":"publisher","first-page":"2459","DOI":"10.1007\/s00296-011-1986-8","volume":"32","author":"SG Lee","year":"2012","unstructured":"Lee SG et\u00a0al (2012) ISN\/RPS 2003 class II mesangial proliferative lupus nephritis: a\u00a0comparison between cases that progressed to class III or IV and cases that did not. Rheumatol Int 32(8):2459\u20132464","journal-title":"Rheumatol Int"},{"issue":"8","key":"496_CR42","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.1093\/ndt\/gfv296","volume":"32","author":"A Malvar","year":"2017","unstructured":"Malvar A et\u00a0al (2017) Histologic versus clinical remission in proliferative lupus nephritis. Nephrol Dial Transplant 32(8):1338\u20131344","journal-title":"Nephrol Dial Transplant"},{"issue":"12","key":"496_CR43","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1038\/nrneph.2012.220","volume":"8","author":"B Sprangers","year":"2012","unstructured":"Sprangers B, Monahan M, Appel GB (2012) Diagnosis and treatment of lupus nephritis flares\u2014an update. Nat Rev Nephrol 8(12):709\u2013717","journal-title":"Nat Rev Nephrol"},{"issue":"suppl_1","key":"496_CR44","doi-asserted-by":"publisher","first-page":"i71","DOI":"10.1093\/ndt\/gfw300","volume":"32","author":"DJ Birmingham","year":"2017","unstructured":"Birmingham DJ et\u00a0al (2017) Biomarkers of lupus nephritis histology and flare: deciphering the relevant amidst the noise. Nephrol Dial Transplant 32(suppl_1):i71\u2013i79","journal-title":"Nephrol Dial Transplant"},{"issue":"11","key":"496_CR45","doi-asserted-by":"publisher","first-page":"2060","DOI":"10.2215\/CJN.00240110","volume":"5","author":"A Smyth","year":"2010","unstructured":"Smyth A et al (2010) A systematic review and meta-analysis of pregnancy outcomes in patients with systemic lupus erythematosus and lupus nephritis. Clin J Am Soc Nephrol 5(11):2060\u20132068","journal-title":"Clin J Am Soc Nephrol"},{"issue":"1","key":"496_CR46","doi-asserted-by":"publisher","first-page":"23","DOI":"10.3109\/10641959809072235","volume":"17","author":"GJ Daskalakis","year":"1998","unstructured":"Daskalakis GJ et\u00a0al (1998) Lupus nephritis and pregnancy. Hypertens Pregnancy 17(1):23\u201330","journal-title":"Hypertens Pregnancy"},{"key":"496_CR47","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.jaut.2017.06.003","volume":"84","author":"D Gianfreda","year":"2017","unstructured":"Gianfreda D et\u00a0al (2017) Does pregnancy have any impact on long term damage accrual and on the outcome of lupus nephritis? J\u00a0Autoimmun 84:46\u201354","journal-title":"J Autoimmun"},{"key":"496_CR48","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.jaut.2016.06.016","volume":"74","author":"MG Lazzaroni","year":"2016","unstructured":"Lazzaroni MG et\u00a0al (2016) A comprehensive review of the clinical approach to pregnancy and systemic lupus erythematosus. J\u00a0Autoimmun 74:106\u2013117","journal-title":"J Autoimmun"},{"issue":"4","key":"496_CR49","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1053\/j.ajkd.2013.10.056","volume":"63","author":"B Bose","year":"2014","unstructured":"Bose B, Silverman ED, Bargman JM (2014) Ten common mistakes in the management of lupus nephritis. Am J Kidney Dis 63(4):667\u2013676","journal-title":"Am J Kidney Dis"},{"issue":"5","key":"496_CR50","doi-asserted-by":"publisher","first-page":"734","DOI":"10.2215\/CJN.10601016","volume":"12","author":"EC Rijnink","year":"2017","unstructured":"Rijnink EC et\u00a0al (2017) Clinical and histopathologic characteristics associated with renal outcomes in lupus nephritis. Clin J Am Soc Nephrol 12(5):734\u2013743","journal-title":"Clin J Am Soc Nephrol"},{"issue":"6","key":"496_CR51","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1016\/j.kint.2016.02.014","volume":"89","author":"L Zhang","year":"2016","unstructured":"Zhang L et al (2016) Long-term outcomes of end-stage kidney disease for patients with lupus nephritis. Kidney Int 89(6):1337\u20131345","journal-title":"Kidney Int"},{"issue":"12","key":"496_CR52","doi-asserted-by":"publisher","first-page":"3623","DOI":"10.1093\/ndt\/gfm459","volume":"22","author":"M Chelamcharla","year":"2007","unstructured":"Chelamcharla M et\u00a0al (2007) The outcome of renal transplantation among systemic lupus erythematosus patients. Nephrol Dial Transplant 22(12):3623\u20133630","journal-title":"Nephrol Dial Transplant"}],"container-title":["Zeitschrift f\u00fcr Rheumatologie"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00393-018-0496-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-018-0496-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-018-0496-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,27]],"date-time":"2019-06-27T19:26:26Z","timestamp":1561663586000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00393-018-0496-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6,28]]},"references-count":52,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2018,9]]}},"alternative-id":["496"],"URL":"https:\/\/doi.org\/10.1007\/s00393-018-0496-4","relation":{},"ISSN":["0340-1855","1435-1250"],"issn-type":[{"value":"0340-1855","type":"print"},{"value":"1435-1250","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,6,28]]},"assertion":[{"value":"28 June 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"S.\u00a0Melderis, T.\u00a0Wiech, C.\u00a0Iking-Konert und O.M.\u00a0Steinmetz geben an, dass kein Interessenkonflikt besteht.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"Dieser Beitrag beinhaltet keine von den Autoren durchgef\u00fchrten Studien an Menschen oder Tieren.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics"}}]}}